MX2009010929A - Terapias de combinacion que comprenden inhibidores de quinoxalina de pi3k-alfa para uso en el tratamiento del cancer. - Google Patents
Terapias de combinacion que comprenden inhibidores de quinoxalina de pi3k-alfa para uso en el tratamiento del cancer.Info
- Publication number
- MX2009010929A MX2009010929A MX2009010929A MX2009010929A MX2009010929A MX 2009010929 A MX2009010929 A MX 2009010929A MX 2009010929 A MX2009010929 A MX 2009010929A MX 2009010929 A MX2009010929 A MX 2009010929A MX 2009010929 A MX2009010929 A MX 2009010929A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- pi3k
- alpha
- treatment
- combination therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona métodos de tratar cáncer por la administración de un compuesto de Fórmula I, opcionalmente en forma de sus sales farmacéuticamente aceptable, sus solvatos y/o hidratos, en combinación con otros tratamientos de cáncer. (ver fórmula I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92316407P | 2007-04-11 | 2007-04-11 | |
PCT/US2008/004570 WO2008127594A2 (en) | 2007-04-11 | 2008-04-08 | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009010929A true MX2009010929A (es) | 2010-01-20 |
Family
ID=39864581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009010929A MX2009010929A (es) | 2007-04-11 | 2008-04-08 | Terapias de combinacion que comprenden inhibidores de quinoxalina de pi3k-alfa para uso en el tratamiento del cancer. |
Country Status (34)
Country | Link |
---|---|
US (1) | US8481001B2 (es) |
EP (1) | EP2139483B9 (es) |
JP (2) | JP5726515B2 (es) |
KR (1) | KR101586774B1 (es) |
CN (2) | CN101959516B (es) |
AU (1) | AU2008239668B2 (es) |
BR (1) | BRPI0810208A2 (es) |
CA (1) | CA2684056A1 (es) |
CO (1) | CO6140024A2 (es) |
CR (1) | CR11099A (es) |
CY (1) | CY1114608T1 (es) |
DK (1) | DK2139483T3 (es) |
EA (1) | EA019064B1 (es) |
EC (1) | ECSP099723A (es) |
ES (1) | ES2438998T3 (es) |
GT (1) | GT200900263A (es) |
HK (1) | HK1140141A1 (es) |
HR (1) | HRP20131081T1 (es) |
IL (1) | IL201211A (es) |
MA (1) | MA31335B1 (es) |
ME (1) | ME00937B (es) |
MX (1) | MX2009010929A (es) |
MY (1) | MY150797A (es) |
NI (1) | NI200900184A (es) |
NZ (1) | NZ580009A (es) |
PL (1) | PL2139483T3 (es) |
PT (1) | PT2139483E (es) |
RS (1) | RS53020B (es) |
SI (1) | SI2139483T1 (es) |
SV (1) | SV2009003390A (es) |
TN (1) | TN2009000399A1 (es) |
UA (1) | UA98141C2 (es) |
WO (1) | WO2008127594A2 (es) |
ZA (1) | ZA200906765B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101538412B1 (ko) * | 2005-10-07 | 2015-07-22 | 엑셀리시스, 인코포레이티드 | PI3Kα의 피리도피리미디논 억제제 |
KR101396783B1 (ko) * | 2005-10-07 | 2014-05-21 | 엑셀리시스, 인코포레이티드 | 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법 |
JP2010500994A (ja) | 2006-08-16 | 2010-01-14 | エグゼリクシス, インコーポレイテッド | Pi3kおよびmekモジュレーターを使用する方法 |
JP2010523670A (ja) * | 2007-04-10 | 2010-07-15 | エクセリクシス, インク. | Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法 |
US8673908B2 (en) | 2008-11-10 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd. | Kynurenine production inhibitor |
DE102009049679A1 (de) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
TW201139436A (en) | 2010-02-09 | 2011-11-16 | Exelixis Inc | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
WO2012006552A1 (en) | 2010-07-09 | 2012-01-12 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
US9670212B2 (en) | 2010-09-14 | 2017-06-06 | Exelixis, Inc. | Inhibitors of PI3K-delta and methods of their use and manufacture |
DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
EA201390582A1 (ru) | 2010-10-20 | 2013-09-30 | Мерк Сероно С.А. Женева | Способ получения замещенных n-(3-аминохиноксалин-2-ил)сульфонамидов и их промежуточных n-(3-хлорхиноксалин-2-ил)сульфонамидов |
DE102010049595A1 (de) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
WO2012065057A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
BR112014005858A2 (pt) * | 2011-09-14 | 2017-06-13 | Exelixis Inc | inibidores de fosfatidilinositol 3-quinase para tratamento de câncer |
WO2013052699A2 (en) * | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
WO2013056067A1 (en) | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Compounds for use in the treatment of basal cell carcinoma |
WO2013063000A1 (en) * | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
SG11201401961UA (en) * | 2011-11-01 | 2014-05-29 | Exelixis Inc | N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies |
WO2013067306A1 (en) * | 2011-11-02 | 2013-05-10 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers |
WO2013101964A1 (en) * | 2011-12-27 | 2013-07-04 | Kadmon Corporation, Llc | Methods for treatment of breast cancer nonresponsive to trastuzumab |
WO2013152717A1 (zh) | 2012-04-10 | 2013-10-17 | 上海昀怡健康管理咨询有限公司 | 稠合嘧啶类化合物,其制备方法,中间体,组合物和应用 |
US9487526B2 (en) | 2012-08-13 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as GPR6 modulators |
JP6441910B2 (ja) | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用 |
WO2015055071A1 (zh) | 2013-10-16 | 2015-04-23 | 上海璎黎药业有限公司 | 稠合杂环化合物、其制备方法、药物组合物和用途 |
JP6526034B2 (ja) | 2014-02-14 | 2019-06-05 | 武田薬品工業株式会社 | Gpr6のピリドピラジンモジュレーター |
US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
WO2019119206A1 (en) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060276527A1 (en) * | 2003-01-17 | 2006-12-07 | Thresold Pharmaceuticals, Inc. | Combination therapies for the treatment of cancer |
NZ565749A (en) * | 2005-08-26 | 2010-12-24 | Serono Lab | Pyrazine derivatives and use as PI3K inhibitors |
KR101538412B1 (ko) * | 2005-10-07 | 2015-07-22 | 엑셀리시스, 인코포레이티드 | PI3Kα의 피리도피리미디논 억제제 |
KR101396783B1 (ko) * | 2005-10-07 | 2014-05-21 | 엑셀리시스, 인코포레이티드 | 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법 |
JP2010500994A (ja) | 2006-08-16 | 2010-01-14 | エグゼリクシス, インコーポレイテッド | Pi3kおよびmekモジュレーターを使用する方法 |
JP5508027B2 (ja) * | 2007-02-22 | 2014-05-28 | メルク セローノ ソシエテ アノニム | キノキサリン化合物及びその使用 |
JP2010523670A (ja) * | 2007-04-10 | 2010-07-15 | エクセリクシス, インク. | Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法 |
JP4623164B2 (ja) * | 2008-08-21 | 2011-02-02 | セイコーエプソン株式会社 | プロジェクタ |
-
2008
- 2008-04-08 MY MYPI20094215 patent/MY150797A/en unknown
- 2008-04-08 KR KR1020097023536A patent/KR101586774B1/ko active IP Right Grant
- 2008-04-08 PT PT87426748T patent/PT2139483E/pt unknown
- 2008-04-08 AU AU2008239668A patent/AU2008239668B2/en not_active Ceased
- 2008-04-08 CN CN2008800173944A patent/CN101959516B/zh not_active Expired - Fee Related
- 2008-04-08 EA EA200970935A patent/EA019064B1/ru not_active IP Right Cessation
- 2008-04-08 PL PL08742674T patent/PL2139483T3/pl unknown
- 2008-04-08 EP EP08742674.8A patent/EP2139483B9/en active Active
- 2008-04-08 BR BRPI0810208-2A2A patent/BRPI0810208A2/pt not_active IP Right Cessation
- 2008-04-08 CN CN2013101161222A patent/CN103202842A/zh active Pending
- 2008-04-08 MX MX2009010929A patent/MX2009010929A/es active IP Right Grant
- 2008-04-08 ME MEP-2009-304A patent/ME00937B/me unknown
- 2008-04-08 WO PCT/US2008/004570 patent/WO2008127594A2/en active Application Filing
- 2008-04-08 RS RS20130486A patent/RS53020B/en unknown
- 2008-04-08 JP JP2010503043A patent/JP5726515B2/ja active Active
- 2008-04-08 ES ES08742674.8T patent/ES2438998T3/es active Active
- 2008-04-08 UA UAA200911452A patent/UA98141C2/ru unknown
- 2008-04-08 DK DK08742674.8T patent/DK2139483T3/da active
- 2008-04-08 NZ NZ580009A patent/NZ580009A/xx not_active IP Right Cessation
- 2008-04-08 CA CA002684056A patent/CA2684056A1/en not_active Abandoned
- 2008-04-08 SI SI200831061T patent/SI2139483T1/sl unknown
- 2008-04-08 US US12/595,236 patent/US8481001B2/en active Active
-
2009
- 2009-09-29 IL IL201211A patent/IL201211A/en active IP Right Grant
- 2009-09-29 ZA ZA200906765A patent/ZA200906765B/xx unknown
- 2009-09-30 TN TNP2009000399A patent/TN2009000399A1/fr unknown
- 2009-10-09 SV SV2009003390A patent/SV2009003390A/es unknown
- 2009-10-09 GT GT200900263A patent/GT200900263A/es unknown
- 2009-10-09 NI NI200900184A patent/NI200900184A/es unknown
- 2009-10-30 MA MA32313A patent/MA31335B1/fr unknown
- 2009-11-09 CR CR11099A patent/CR11099A/es unknown
- 2009-11-09 EC EC2009009723A patent/ECSP099723A/es unknown
- 2009-11-09 CO CO09126923A patent/CO6140024A2/es unknown
-
2010
- 2010-07-05 HK HK10106504.4A patent/HK1140141A1/xx not_active IP Right Cessation
-
2013
- 2013-11-01 JP JP2013228684A patent/JP2014074031A/ja active Pending
- 2013-11-12 HR HRP20131081AT patent/HRP20131081T1/hr unknown
- 2013-11-15 CY CY20131101016T patent/CY1114608T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1140141A1 (en) | Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
HK1139863A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
TN2012000622A1 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
MY146111A (en) | Acylaminopyrazoles as fgfr inhibitors | |
TW200738725A (en) | Unsaturated mTOR inhibitors | |
MX2009009786A (es) | Inhibidores de la via de hedgehog. | |
MX2016001793A (es) | Terapia de combinacion para el tratamiento del cancer. | |
TW200722083A (en) | Combinations and methods of using an indolinone compound | |
MX354509B (es) | Combinaciones de compuestos inhibidores de akt y vemurafenib y metodos de uso de los mismos. | |
TN2011000298A1 (en) | Compounds useful for inhibiting chk1 | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
NZ590550A (en) | Inhibitors of Apoptosis (IAP) for treating cancer | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
MX2010004967A (es) | Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso. | |
MX2009006574A (es) | Tratamiento de cancer de pulmon. | |
UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
EA200870454A1 (ru) | Способ ингибирования c-kit киназы | |
JO3145B1 (ar) | مركبات مفيدة لتثبيط chk1 | |
IN2012DN02816A (es) | ||
WO2007136615A3 (en) | Combination cancer therapy | |
WO2008015538A3 (en) | Use of diaza- and thiaza-cycloalkanediones for preventing and/or treating pain and /or migraine | |
CY1114609T1 (el) | Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας αναστολεις p13k αλφα με βαση πυριδοπυριμιδινονη | |
UA99612C2 (en) | Inhibitors of the hedgehog pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |